By Hazel Dawson
The gulf between US and European biotech fundraising isn't new. Despite the number of companies being similar on both sides...
Working Around Pre-Emption Rights
Europe's pre-emption rights significantly hamper biotech fundraising. But since they're unlikely to go away, European firms are having to find clever ways around them.
More from Strategy
More from Business
• By
Multi-blockbuster falls short in a giant cell arteritis study.
• By
Deal Snapshot: Having recently raised an $89m IPO, BioVersys is partnering on and optioning rights to a preclinical NTM development program with Shionogi.
• By
The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.